Curriculum Vitae For:

Jeffrey Marc Frankel, MD

Jeffrey Marc Frankel, MD

16259 Sylvester Road Southwest, Suite 303
Seattle, WA 98166

Office Phone: 206.244.2822

Office Fax: 206.243.7807

Credentials:

Medical License: Washington MD00022889

Diplomate: American Board of Medical Examiners
Certification: American Board of Urology, 1987, Re-certified, 1995, 2005

Education:
1971 – 1975 BS – Biology/Psychology, University of Washington, Seattle,
Washington
1975 – 1979 MD – University of Washington, Seattle, Washington
1979 – 1980 Internship: San Diego Veterans Administration Hospital – Surgery, La
Jolla, California
1979 – 1980 Internship: University Hospital, San Diego, California
1980 – 1981 Residency: City of Hope Hospital, Durante, California
1980 – 1981 Surgical Residency: San Diego Veterans Administration Hospital, La Jolla,
California
1980 – 1981 Residency: University Hospital, San Diego, California
1981 – 1985 Urology, Baylor College of Medicine Affiliated Hospitals, Houston,
Texas
Endourology and Extracorporeal Shock Wave Lithotripsy
Genitourinary Prosthetics
Microvascular Surgery (80 hour instructional course)

Work Experience:
2005 - Present Medical Director Seattle Urology Research Center
1991 – Present Clinical Research: Principal and Sub Investigator
1988 – Present Physician – Private Practice Urology; 16259 Sylvester Road
Southwest, Suite 303, Seattle, Washington
1985 – 1987 Private Urology Practice – Kent Medical Center, Kent, Washington

Hospital Affiliations:

1987 – Present Active Staff, Highline Medical Center, Seattle, Washington

1985 – Present Active Staff, Valley Medical Center, Kent, Washington
1985 – 2000 Active Staff, Virginia Mason Hospital, Seattle, Washington

September 2007 1
 Curriculum Vitae For:
Jeffrey Marc Frankel, MD
Board of Director Affiliations:

03/15/2009-03/21/2010 President, American Association of Clinical Urologists (AACU)

01/01/2008-12/31/2009 Chief of Staff Highline Medical Center

01/01/2006-12/31/2007 President Elect Highline Medical Center

01/01/2006 – Present Board of Trustees: Highline Medical Center

03/30/2008-03/31/2009 President Elect, American Association of Clinical Urologists

03/2005 – Present Board of Directors Western Region Representative America Association

of Clinical Urologist

2005 – 2006 President, Washington State Urological Society, Washington

2005 – Present Medical Director, Seattle Urology Research Center

2004 – 2005 Secretary/Treasurer, Medical Executive Committee, Highline

Medical Center

2003 – 2004 President Elect, Washington State Urological Society, Washington

2000 – 2002 Board of Directors, Western Section, American Urological Association

1995 – 1996 Board of Directors, Highline Medical Service Organization

Seattle, Washington
1994 – 1995 Board of Directors, Highline Hospital Foundation, Seattle,
Washington

1993 – 1995 Chief of Surgery, Highline Medical Center, Seattle, Washington

Professional Affiliations
Active Member, Washington State Urological Society
Active Member, Northwest Urological Association
Active Member, King County Medical Society
Active Member, American Urological Association, Western Section
Active Member, American Urological Association
Active Member, American Association of Clinical Urologists
Research Activities:

1. A two Phase, Double-Blinded, Randomized, Parallel-Group Design, Multicenter

Study Of XXXXX Versus XXXXX In Male Patients With Acute Urinary
Retention Related To Benign Prostatic Hyperplasia

2. A long-Term, Open-Label Clinical Study Evaluating the Safety and Efficacy of

XXXXX in Subjects with Symptomatic Benign Prostatic Hyperplasia (BPH).

3. A Multi-Center, Multi-Market Survey To Evaluate The Potential Enrollment Rate

Using a Media-Based Recruitment Program In A Population Of Men Aged Greater
Than 40 Years With Mild To Moderate Signs And Symptoms Of Benign Prostatic
Hyperplasia.

September 2007 2
 Curriculum Vitae For:
Jeffrey Marc Frankel, MD
4. A Double-Blind, Randomized, Parallel Group Trial of XXXXX® Extended
Release Tablets or Placebo In Combination with XXXXX® For the Treatment Of
Lower Urinary Tract Symptoms (Protocol CAPSS-292)

5. A Multi-Center, Double-Blind, Double-Dummy, Randomized, Placebo And

XXXXX Controlled Parallel Group Study To Assess The Efficacy And Safety Of
XXXXX In Subjects With Lower Urinary Tract Symptoms Due To Benign
Prostatic Obstruction

6. Long-Term Efficacy And Safety Of XXXXX On The Risk Of Acute Urinary

Retention And The Need For Surgery In Patients With BPH. A Two-Year,
Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study

7. A Phase II/III, Double-Blind, Placebo Controlled, Dose-Finding Study Of The

Safety And Efficacy Of XXXXX In Patients With Symptomatic Benign Prostatic
Hyperplasia (BPH).

8. A Double-Blind Placebo-Controlled, Parallel-Group Safety and Efficacy Study

Evaluating Three Dose Regiments Of XXXXX, A Selective Alpha-Adrenergic
Antagonist, In The Treatment Of Benign Prostatic Hyperplasia

9. An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo

Lead-In Study Of XXXXX Capsules, 0.4mg Daily Versus XXXXX Capsules, 5mg
(With XXXXX) Daily In Patients With The Signs And Symptoms Of Benign
Prostatic Hyperplasia.

10. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed-Dose,

Parallel Group, 6-Month Comparison Study To Investigate The Efficacy and Safety
Of XXXXX In Males With Erectile Dysfunction

11. A Randomized, Double-Blind, Parallel, Placebo-Controlled Study In Men With

Erectile Dysfunction To Evaluate The Efficacy And Safety Of XXXXX When Sexual
Attempts Occur At Specific Time Points After Dosing

12. An Open-Label, Non-Controlled, Fixed-Dose, Sequential Dose-Ranging Study To

Evaluate The Safety, Tolerance, Pharmacokinetics And Hormonal Efficacy Of
Monthly Doses Of XXXXX In Patients With Advanced Prostate Cancer

13. An Open-Label, Randomized, Multi-Center, Parallel Group Comparison Of The

Efficacy And Safety Of XXXXX At Two Different Dosing Regiments In Patients
With Prostate Cancer Dosed For Thirteen 28-day Cycles

14. A Phase II Study Evaluating The Safety And Efficacy Of XXXXX In Men With
Hormone Naïve Prostate Cancer That Are Exhibiting Early Signs Of Biochemical
Failure.

15. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety

And Efficacy Of XXXXX mg XXXXX In Men With Metastatic, Hormone-
Refractory Prostate Cancer

16. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety

And Efficacy Of XXXXX mg XXXXX In Men With Non-Metastatic, Hormone-
Refractory Prostate Cancer
September 2007 3
 Curriculum Vitae For:
Jeffrey Marc Frankel, MD

17. A Phase III Extension Study To Evaluate The Safety Of XXXXX mg XXXXX In
Men With Hormone-Refractory Prostate Cancer.

18. Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To

Assess The Safety And Efficacy Of XXXXX In Delaying The Systemic
Progression Of Prostate Cancer In Patients With Intermediate To High Risk Of
Recurrence With Rising Prostate Specific Antigen (PSA) Levels After
Prostatectomy, Prostatectomy And Radiotherapy, Or Radiotherapy Alone For
Localized Disease

19. A Phase III, Randomized Mulitcenter, Placebo-Controlled, Double-blind Clinical

Trial To Study The Efficacy And Safety Of XXXXX For The Treatment Of Hot
Flashes Following Surgical Or Chemical Castration Of Prostate Cancer Patients
And Its Impact On The Quality Of Life In These Patients

20. A Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose,

Multicenter Study To Assess Efficacy And Safety Of Daily Oral Administration
of XXXXX Versus Placebo In Male And Female Subjects With Overactive
Bladder

21. An Open-Label, Long Term Tolerability Study Of Daily Oral Administration Of

XXXXX In Male And Female Subjects With Overactive Bladder

22. A 6-Week, Double-Blind, Placebo Controllekd, Randomized, Parallel Group,

Multicenter, Multidose Study Of The Efficacy And Safety Of XXXXX In Patients
With Overactive Bladder Symptoms Of Increased Urinary Frequency, Urgency, And
Urge Incontinence

23. Study Of XXXXX In Women Of Different Demographic Characteristics And

Co morbidities With Stress Urinary Incontinence: Evaluation Of Efficacy And Safety

24. McNeil Consumer & Specialty Pharmaceuticals, “A Placebo-Controlled Study

Evaluating The Safety And Efficacy Of XXXXX 3mg And 5mg In Women With
Overactive Bladder”

25. Double-Blind, Placebo Controlled Study Of XXXXX In Subjects With

Symptoms Of Overactive Bladder Of Urgency, Frequency And Urinary Incontinence

26. Open-Label Extension Study Of Sustained Release XXXXX In Subjects With

Symptoms Of Overactive Bladder

27. A Double-Blind, Placebo-Controlled, Randomized US Study To Evaluate The

Effect Of XXXXX On Nocturia In Patients With Symptoms Of Overactive Bladder

28. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing

XXXXX Transdermal Systems Versus XXXXX Long Acting Capsules In Patients
With Overactive Bladder

29. A Dose-Range Study To Evaluate XXXXX, XXXXX, And XXXXX When

September 2007 4
 Curriculum Vitae For:
Jeffrey Marc Frankel, MD
Administered To Female Subjects With Unstable Bladder Conditions

30. XXXXX In Patients With Urge Urinary Incontinence: A 12-Week Multi-Center,

Randomized, Double-Blind, Placebo-Controlled Study With A 12-Week Open-
Label, Dose-Titration, Safety Extension.

31. Prospective, Randomized, Double-Blind Multi-Center, Comparative Trial To

Evaluate The Efficacy And Safety Of XXXXX Once-Daily (QD) Modified Release
(XXXXX MR) Tablets 1000Mg Conventional XXXXX 500 Mg Tablets In The 7-
14 Day Treatment Of Patients With Complicated Urinary Tract Infections (cUTI)
Or Acute, Uncomplicated Pyelonephritis

32. A Multi-Center, Randomized, Double blind, Placebo – Controlled, Parallel Evaluation of

the Efficacy and Safety of xxxxxxxx in the treatment of the Signs and Symptoms of
Benign Prostatic Hyperplasia.

33. A Multi-Center Open Label Evaluation of the Safety of xxxxxxxxx in the Treatment of
the Symptoms of Benign Prostatic Hyperplasia.

34. An Open Label Multi-Center, Randomized, Parallel-Group study Investigating, the

Efficacy and Safety of xxxxxxxx on Month dosing regimen in comparision to xxxxxx
Depot, in patients with prostate cancer requiring Androgen Ablation Therapy.
\
35. An Open Label , Multi-Center Extension Study, Investigating Long Term Safety and
Tolerability of xxxxxxxxx one month Depots in Patients with Prostate Cancer.

36. A Phase 2, Randomized , Multi-Center, Placebo-Controlled, Double-Blind, Dose

Treatment of Hot Flashes following Surgical or Medical Castration of Prostate.

37. A Multicenter , Double-Blind, Placebo controlled, Flexible- Dose Study with an Open
Label Phase to asses the Efficacy of xxxxxxxxxxx xxxxxxx On Erectile Function and
intercourse satisfaction as well as to Validate the Sexual experience Questionnaire and its
Treatment Responsiveness in man with Erectile Dysfunction.

38. A Randomized, Double-Blind Placebo-Controlled, Multi-Center Phase 3 of xxxxxxxxxx

on Prolonging Bone Metastasis Free Survival in Men with Refractory Prostate Cancer.

39. A Phase 3 Extension Study to Evaluate the Safety of xxxxxxxxxxxx, in Man with
Hormone-Refractory Prostate Cancer.

40. Preliminary Efficacy and Safety of xxxxxxxxx in the Treatment of Hypogonadism: A 4

week, Randomized, double-Blind, Placebo-Controlled, Parallel-Group Study Comparing
Daily Oral of xxxxxxxxxxx and Placebo.

September 2007 5
 Curriculum Vitae For:
Jeffrey Marc Frankel, MD

Publications:

1. Condyloma Acuminatum Of The Bladder And Associated Urothelial Malignancy;

“Journal Of Urology”, Vol. 134: 134-136, Jul, 1985

2. The Prognostic Significance Of Post-Irradiaton Biopsy Results In Patients With

Prostatic Cancer; “Journal Of Urology”, Vol. 135 (3): 510-516, Mar, 1986

3. Extracorporal Shock Wave Lithotripsy with a transportable electrohydraulic Lithotripter:

Experience with > 300 Patients, British Journal of Urology International, Vol 98-003-007,
2005

September 2007 6